PROBIOTIX HEALTH PLC - Audited results for the year ended 31 December 2025

ProBiotix Health PLC (AQUIS:PBX) delivered a strong 2025 investor update, reporting robust revenue growth of 45 percent to 2.7 million, improved EBITDA performance with reduced losses, and stable gross margins of 54 percent, reflecting disciplined cost control and scalable operations. The company expanded its customer base by 70 percent, strengthened its order book, and increased pipeline visibility with 76 active projects, supporting future revenue and profitability. Growth was driven by international expansion across Europe, North America, and China, alongside a diversified business model spanning bulk ingredients and white label solutions. Continued investment in clinical development and proprietary probiotic technology underpins its long term growth strategy, particularly in cardio metabolic health. Strategic partnerships, rising digital lead generation, and entry into new segments such as menopause health further enhance commercial momentum. With a solid cash position and a profitable start to 2026, the company is well positioned to capitalise on regulatory tailwinds, expand margins, and accelerate global market penetration, reinforcing confidence in its path toward sustainable profitability and scalable growth.